Filing Details

Accession Number:
0001209191-20-059055
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-18 16:11:01
Reporting Period:
2020-11-16
Accepted Time:
2020-11-18 16:11:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557290 A Stuart Arbuckle C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-11-16 2 $222.47 35,184 No 4 S Direct
Common Stock Disposition 2020-11-16 5 $224.11 35,179 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 140 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $222.47 (range $222.30 to $222.63).
  3. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $224.11 (range $223.77 to $224.56).